At Mirati, we convert possibility into reality by developing best-in-class targeted therapies to improve the lives of patients.
Our scientists are rigorously advancing research and development programs targeting the KRASG12C and KRASG12D mutations.
We are exploring new ways of targeting the protective nest of cells, tissues and blood vessels that make up the tumor microenvironment.
MRTX1719 is an investigational, internally discovered synthetic lethal PRMT5 inhibitor for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO